NuCana (NCNA) Competitors $4.68 +0.05 (+1.08%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.79 +0.11 (+2.37%) As of 10/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NCNA vs. ORGS, BON, PBLA, VINC, VRPX, SMFL, SCPS, ARDS, NAVB, and EVLOShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Orgenesis (ORGS), Bon Natural Life (BON), Panbela Therapeutics (PBLA), Vincerx Pharma (VINC), Virpax Pharmaceuticals (VRPX), Smart for Life (SMFL), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Its Competitors Orgenesis Bon Natural Life Panbela Therapeutics Vincerx Pharma Virpax Pharmaceuticals Smart for Life Scopus BioPharma Aridis Pharmaceuticals Navidea Biopharmaceuticals Evelo Biosciences NuCana (NASDAQ:NCNA) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation. Does the media refer more to NCNA or ORGS? In the previous week, NuCana's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score. Company Overall Sentiment NuCana Neutral Orgenesis Neutral Is NCNA or ORGS more profitable? NuCana has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets NuCanaN/A -592.28% -208.68% Orgenesis -3,827.81%N/A -130.18% Do analysts prefer NCNA or ORGS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, NCNA or ORGS? NuCana has higher earnings, but lower revenue than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuCanaN/AN/A-$24.28M-$646.16-0.01Orgenesis$662K0.37-$55.36MN/AN/A Which has more risk & volatility, NCNA or ORGS? NuCana has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Do institutionals & insiders believe in NCNA or ORGS? 44.0% of NuCana shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryNuCana beats Orgenesis on 5 of the 9 factors compared between the two stocks. Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$141K$3.33B$6.08B$10.54BDividend YieldN/A2.27%5.68%4.70%P/E Ratio-0.0122.1478.0526.71Price / SalesN/A421.51579.60179.64Price / CashN/A47.2037.7961.25Price / Book0.029.9312.556.56Net Income-$24.28M-$52.80M$3.31B$277.70M7 Day Performance16.71%5.22%4.28%2.41%1 Month Performance63.64%13.01%7.85%9.30%1 Year Performance-98.82%25.18%71.37%31.22% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana0.6017 of 5 stars$4.68+1.1%N/A-98.8%$141KN/A-0.0130Positive NewsORGSOrgenesisN/A$0.07-92.8%N/A-98.8%$346K$662K0.00150Gap DownBONBon Natural Life0.5481 of 5 stars$1.97+1.2%N/AN/A$335K$23.84M0.00100Short Interest ↑PBLAPanbela Therapeutics0.1179 of 5 stars$0.05flatN/A-96.9%$243KN/A0.006VINCVincerx Pharma2.5696 of 5 stars$0.04-4.7%$40.00+99,402.5%-99.6%$210KN/A0.0060Short Interest ↑Gap UpVRPXVirpax Pharmaceuticals0.0585 of 5 stars$0.04+39.8%N/A-99.9%$44KN/A0.007Gap DownSMFLSmart for LifeN/A$0.01-16.7%N/A-85.0%$35K$11.11M0.00110Gap DownSCPSScopus BioPharmaN/A$0.00flatN/A+0.0%$13KN/A0.009ARDSAridis PharmaceuticalsN/A$0.00-88.2%N/AN/A$11KN/A0.0030Gap DownHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00-50.0%N/A-90.0%$10K$8.13K0.0010EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions Volume Related Companies and Tools Related Companies Orgenesis Competitors Bon Natural Life Competitors Panbela Therapeutics Competitors Vincerx Pharma Competitors Virpax Pharmaceuticals Competitors Smart for Life Competitors Scopus BioPharma Competitors Aridis Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NCNA) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
